

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below.	
October 9, 2001 Date	Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Brent Iverson et al.

Serial No.: 09/813,444

Filed: March 20, 2001

For: DIRECTED EVOLUTION OF ENZYMES  
AND ANTIBODIES

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: MXGN:005USC2/SLH

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES DATED AUGUST 6, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 6, 2001 for which the two-month date for response is October 6, 2001.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10102539/SLH.

**RESPONSE TO NOTICE**

Submitted herewith is a Statement As Required Under 37 C.F.R. § 1.821(f); paper copy of sequence listing and computer readable form (CRF) which comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Applicants believe that the attached documents fully respond to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures for this application.

Respectfully submitted,



Steven J. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: October 9, 2001



AP SECTOR

Box SEQ

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

WRITER'S INTERNET ADDRESS:  
GSHISHIMA@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3081

October 9, 2001

FILE: MXGN:005USC2  
10102539

### CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

October 9, 2001  
Date

Steven L. Highlander

### BOX MISSING PARTS

Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application No. 09/813,444 Entitled: DIRECTED EVOLUTION OF ENZYMES AND ANTIBODIES - by Brent Iverson et al.*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- (2) Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Dated August 6, 2001;
- (3) Statement as Required Under 37 C.F.R. § 1.821(f); Paper Copy of Sequence Listing; Computer Readable Form (CRF); and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.


Commissioner for Patents

October 9, 2001

Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10102539/SLH.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "SLH".

Steven L. Highlander  
Reg. No. 37,642

SLH/cpj

Encl.: As stated